Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy - Bibi, S.; Arslanhan, M. D.; Langenfeld, F.; Jeanningros, S.; Cerny-Reiterer, S.; Hadzijusufovic, E.; Tchertanov, L.; Moriggl, R.; Valent, P.; Arock, M. (Haematologica (Roma), 2014)
Keywords: Animals; Fusion Proteins, bcr-abl - genetics; Fusion Proteins, bcr-abl - metabolism; Humans; Janus Kinases - metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - etiology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Life Sciences; Mast Cells - metabolism; Mast Cells - pathology; Mastocytosis - drug therapy; Mastocytosis - etiology; Mastocytosis - metabolism; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases - metabolism; Proto-Oncogene Proteins c-akt - antagonists & inhibitors; Proto-Oncogene Proteins c-akt - metabolism; Proto-Oncogene Proteins c-kit - genetics; Proto-Oncogene Proteins c-kit - metabolism; Review; Signal Transduction - drug effects; STAT5 Transcription Factor - antagonists & inhibitors; STAT5 Transcription Factor - metabolism